Criteria to qualify for this study: Drug used in study:
  • Relapsed of refractory multiple myeloma Or relapsed or refractory B-Cell NHL
    After at least 2 prior regimens

HR 59

A Phase Ia/Ib open –label, multicenter study evaluating the safety and pharmacokinetics of Tiragolumab as a single agent and in combination with Daratumumab in patients with relapsed or refractory Multiple Myeloma, and as a single agent and in combination with Rituximab in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma
Criteria to qualify for this study: Drug used in study:
  • Measurable disease defined as serum M protein >200mg/24 hours, or serum FLC (sFLC) assay: involved FLC level >10mg/dl provided sFLC ratio is abnormal.

MM 95

A Phase 1, First in Man, Multicenter, Open-Label, two part dose escalation and cohort expansion study of Single-Agent GBR 1342 in subjects with previously treated Multiple Myeloma
Criteria to qualify for this study: Drug used in study:
  • Relapsed CAR-T

MM 88 Poseida PBMCS – 101 – 001

Open-Label, Multi-Center, Single Ascending Dose Study to Assess the Safety of P-BMCA-101 in Subjects with Relapsed and/or Refractory Multiple Myeloma.

Criteria to qualify for this study: Drug used in study:
  • Relapsed / Refractory
  • 2 part, multicenter, open label, phase 1a/1b study of TTI-622 in patients with advanced relapsed or refractory lymphoma and multiple myeloma

HR 56 TTI-622-01

A Phase 1a/1b dose escalation and expansion trial of TTI-622 in patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.